

UNITED STATES BANKRUPTCY COURT

Northern DISTRICT OF Texas

In re: Eiger BioPharmaceuticals, Inc

§
§
§
§

Case No. 24-80040

Lead Case No. 24-80040

Debtor(s)

☒ Jointly Administered

Post-confirmation Report

Chapter 11

Quarter Ending Date: 12/31/2024

Petition Date: 04/01/2024

Plan Confirmed Date: 09/05/2024

Plan Effective Date: 09/30/2024

This Post-confirmation Report relates to: ☒ Reorganized Debtor

☐ Other Authorized Party or Entity:

Name of Authorized Party or Entity

/s/ Gary Broadbent

Signature of Responsible Party

02/07/2025

Date

Gary Broadbent

Printed Name of Responsible Party

1209 Orange Street, Wilmington, Delaware 19801.

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.



2480040250207000000000003

Debtor's Name Eiger BioPharmaceuticals, Inc

Case No. 24-80040

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$3,108,630	\$3,108,630
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$3,108,630	\$3,108,630

Part 2: Preconfirmation Professional Fees and Expenses

a.			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor		\$4,754,245	\$12,891,365	\$4,754,245	\$12,891,365
Itemized Breakdown by Firm						
	Firm Name	Role				
i	Alvarez & Marsal	Financial Professional	\$513,036	\$3,452,114	\$513,036	\$3,452,114
ii	KCC, LLC	Other	\$112,766	\$953,110	\$112,766	\$953,110
iii	Sidley Austin LLP	Lead Counsel	\$4,128,443	\$8,331,110	\$4,128,443	\$8,331,110
iv	SSG Advisors, LLC	Other	\$0	\$155,031	\$0	\$155,031
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						

Case No. 24-80040

xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						

Debtor's Name Eiger BioPharmaceuticals, Inc

Case No. 24-80040

lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcix						
c						
ci						

b.			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor					
	<i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
i						
ii						
iii						
iv						
v						
vi						

Debtor's Name Eiger BioPharmaceuticals, Inc

Case No. 24-80040

	vii					
	viii					
	ix					
	x					
	xi					
	xii					
	xiii					
	xiv					
	xv					
	xvi					
	xvii					
	xviii					
	xix					
	xx					
	xxi					
	xxii					
	xxiii					
	xxiv					
	xxv					
	xxvi					
	xxvii					
	xxviii					
	xxix					
	xxx					
	xxxi					
	xxxii					
	xxxiii					
	xxxiv					
	xxxv					
	xxxvi					
	xxxvii					
	xxxviii					
	xxxix					
	xl					
	xli					
	xlii					
	xliii					
	xliv					
	xlv					
	xlvi					
	xlvii					
	xlviii					

Debtor's Name Eiger BioPharmaceuticals, Inc

Case No. 24-80040

xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						

Debtor's Name Eiger BioPharmaceuticals, Inc

Case No. 24-80040

	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and expenses (debtor & committees)			\$5,688,371	\$13,825,491	\$5,688,371	\$13,825,491

Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$0	\$0	\$0	\$0	0%
b. Secured claims	\$0	\$0	\$0	\$0	0%
c. Priority claims	\$0	\$0	\$0	\$0	0%
d. General unsecured claims	\$5,000,000	\$0	\$0	\$0	0%
e. Equity interests	\$7,000,000	\$0	\$0		

Part 4: Questionnairea. Is this a final report? Yes ☐ No ☒

If yes, give date Final Decree was entered: _____

If no, give date when the application for Final Decree is anticipated: _____

b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ☒ No ☐

Debtor's Name Eiger BioPharmaceuticals, Inc

Case No. 24-80040

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ Gary Broadbent

Signature of Responsible Party

Plan Administrator

Title

Gary Broadbent


Printed Name of Responsible Party

02/07/2025


Date

Debtor's Name Eiger BioPharmaceuticals, Inc


Case No. 24-80040




Page 1




Other Page 1




Page 2 Minus Tables




Bankruptcy Table 1-50




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page

ADDENDUM

General. On September 30, 2024, Eiger BioPharmaceuticals Inc., *et al.*, distributed \$12,300,000 to the Eiger BioPharmaceuticals Inc., *et al.* Litigation Trust, and on October 23, 2024 and October 24, 2024, Eiger InnoTherapeutics Inc. distributed \$1,450,000 (collectively, the “Trust Assets”) in accordance with the Debtors' confirmed chapter 11 plan. As the estate has already paid U.S. Trustee fees on the \$12,300,000 of Trust Assets as they entered the Eiger BioPharmaceuticals Inc., *et al.* Litigation Trust, it need not pay U.S. Trustee fees again when those same Trust Assets are distributed to creditors under the Plan.

Part 3(d) and Part 3(e). So far as certain unliquidated claims have not yet been resolved, it is impossible to determine with specificity what general unsecured claims are anticipated to receive, but we have estimated \$5,000,000. The same holds true for equity interests, which will only be paid after unsecured claims are paid in full based upon funds currently on hand -- we are estimating a \$7,000,000 distribution to equity at this time.